

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Final draft guidance**

(when no draft guidance was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
No.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
The committee noted that people from Black, African and Caribbean family backgrounds are more likely to have an aggressive form of hormone-sensitive metastatic prostate cancer. But it concluded that its recommendation for darolutamide with ADT and docetaxel would not have an effect on people protected by equality legislation different from the effect on the wider population.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
--

N/A.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

N/A.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A.

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, section 3.18.

**Approved by Associate Director (name):** Ross Dent

**Date:** 20/04/2023